A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
Centre Francois Baclesse
Baylor College of Medicine
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.
University of Washington
Cedars-Sinai Medical Center
Merck Sharp & Dohme LLC
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Dana-Farber Cancer Institute
Royal Marsden NHS Foundation Trust
Leap Therapeutics, Inc.
Taiho Oncology, Inc.
Hanmi Pharmaceutical Company Limited
Sanofi
Ruijin Hospital
Imugene Limited
National Cancer Center Hospital East
Duke University
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Stanford University
Highlight Therapeutics
AstraZeneca
BeiGene
Albert Einstein College of Medicine
Rain Oncology Inc
Vanderbilt-Ingram Cancer Center
Janssen Pharmaceutical K.K.
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
NYU Langone Health
Duke University
Five Prime Therapeutics, Inc.
Columbia University
Big Ten Cancer Research Consortium
Stanford University
Jiangsu HengRui Medicine Co., Ltd.
Memorial Sloan Kettering Cancer Center
pharmaand GmbH
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Memorial Sloan Kettering Cancer Center
OncXerna Theraputics, Inc.